Home

BRIAN A MARKISON

CIK 1283061 · CEO · last filed 2025-03-07

BRIAN A MARKISON is a CEO who has filed 90 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for LNTH, was dated Mar 7, 2025. Across all open-market trades the lifetime net is −$6.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $24.6M across reported positions. 34 SEC filings were submitted jointly with Lantheus Holdings, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$24.62M

Companies

9

Total Filings

90

Lifetime Open-Market Net

-$6.19M

Filer Profile

Reported Address
501 FIFTH STREET
BRISTOL, TN 37620
Related Filers
Lantheus Holdings, Inc. — 34 joint filings, latest 2025-03-07
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LNTH CEO 232,420 $100.25 $23.30M -$6.52M 32 2025-03-07
RVL Pharmaceuticals plc (RVLP) Delisted Chief Executive Officer 2,976,020 $0.03 $83.9K $1.32M 1 2022-08-09
RVL Pharmaceuticals plc (OSMT) Delisted Chief Executive Officer 2,126,020 $1.11 $2.36M $0 3 2021-11-08
Organogenesis Holdings Inc. (AHPAW) Delisted Director — $0.69 — $0 5 2018-12-12
IMMUNOMEDICS INC (IMMU) Delisted Director 90,788 — — -$167.8K 16 2017-11-21
ALERE INC. (ALR) Delisted Director 0 $1.32 $0 $0 4 2017-10-03
Organogenesis Holdings Inc. (AHPAU) Delisted Director — $6.16 — $0 1 2016-11-29
Altimmune, Inc. (PIP) Delisted Director — — — $0 4 2015-01-05
KG President and CEO 200,760 $6.57 $1.32M -$817.7K 24 2011-02-02

Recent Filings

90 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-03-07 LNTH Grant (A) +70,909 $0 EDGAR
2025-03-05 LNTH Tax (F) −8,637 -$819.3K EDGAR
2024-12-23 LNTH Mixed +17,322 -$1.11M EDGAR
2024-03-05 LNTH Grant (A) +131,496 $0 EDGAR
2023-05-15 LNTH Grant (A) +2,012 $0 EDGAR
2023-03-29 LNTH Sell (S) −13,290 -$1.08M EDGAR
2022-09-12 LNTH Mixed −17,360 -$3.07M EDGAR
2022-09-08 LNTH Mixed — -$99.4K EDGAR
2022-08-09 RVL Pharmaceuticals plc (RVLP) Delisted Buy (P) +850,000 $1.32M EDGAR
2022-05-12 LNTH Grant (A) — $0 EDGAR
Showing 1–10 of 90
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.